FDA rejected Eli Lilly’s request to sell a new lung-cancer drug in the U.S. that had been largely developed in China
The U.S. Food and Drug Administration rejected an application by Eli Lilly & Co. and a China-based partner to sell a new lung-cancer drug in the U.S.
, afterThe FDA was unable to approve the application, and recommended that an additional clinical trial of the drug be conducted in multiple regions, Lilly said Thursday.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Eli Lilly's BLA for sintilimab can't be approved by FDA in present formEli Lilly & Co. undefined said Thursday it received a complete response letter (CRL) from the U.S. Food and Drug Administration regarding its Biologics...
Leer más »
FDA probe of Abbott facility finds quality control issuesAn inspection at the Abbott Laboratories facility in Sturgis, Michigan found a harmful bacteria on surfaces in some areas of its powdered baby formula production, the U.S. health regulator said on Tuesday.
Leer más »
Moderna wants the FDA to authorize its COVID-19 vaccine for kids under 6Moderna wants the FDA to authorize its COVID-19 vaccine for kids under six. Here's what's next in the process. | via NPR
Leer más »
Moderna will seek FDA emergency use authorization for its vaccine in kids under 6
Leer más »
FDA details problems at plant behind recalled baby formulaAmong other problems, FDA inspectors found a history of contamination with the bacteria, known as cronobacter, in various parts of the plant.
Leer más »